Trial Profile
Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- Acronyms TAR-PRO
- 12 Oct 2023 Status changed from active, no longer recruiting to completed.
- 17 Nov 2020 Results published in the Journal of Antimicrobial Chemotherapy
- 06 Aug 2019 Planned End Date changed from 1 Jun 2019 to 31 Jul 2021.